ACOR Stock Overview
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
Acorda Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.37|
|52 Week High||US$4.90|
|52 Week Low||US$0.26|
|1 Month Change||-1.50%|
|3 Month Change||-15.79%|
|1 Year Change||-91.16%|
|3 Year Change||-97.71%|
|5 Year Change||-99.76%|
|Change since IPO||-99.09%|
Recent News & Updates
Acorda inks license deal with Asieris for pre-clinical drug
Commercial-stage biopharmaceutical company Acorda Therapeutics (NASDAQ:ACOR) announced a license agreement with Chinese biotech Asieris Pharmaceuticals on Monday for the preclinical candidate, Nepicastat. Per the terms, the two companies will collaborate to develop Nepicastat, a small molecule drug for non-psychiatric indications and therapeutic uses. In return, Acorda (ACOR) is set to receive $500K of upfront payment, up to $7M of fees based on regulatory milestones, and a royalty on future net sales. Acorda (ACOR) U.S. subsidiary, Biotie Therapies, Inc., owns the rights for Nepicastat. Read: In June, the nano-cap ACRO stock surged in reaction to the launch of its inhalational Parkinson’s disease drug Inbrija in Germany. However, the company shares remain ~90% below the year-ago level, as indicated in this graph.
Acorda Therapeutics announces resignation of COO
Acorda Therapeutics (NASDAQ:ACOR) has announced that Lauren Sabella, Chief Operating Officer, will resign from the Co. effective Sept. 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. Ms. Sabella’s responsibilities will be assumed by two of her current direct reports, Sofia Ali, Senior VP, Operations & Strategic Planning and Susan Way, Senior VP, Drug Development and Regulatory Affairs. ACOR +4.35% premarket to $0.48.
|ACOR||US Biotechs||US Market|
Return vs Industry: ACOR underperformed the US Biotechs industry which returned -19.3% over the past year.
Return vs Market: ACOR underperformed the US Market which returned -18.8% over the past year.
|ACOR Average Weekly Movement||12.0%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: ACOR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ACOR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson’s disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
Acorda Therapeutics Fundamentals Summary
|ACOR fundamental statistics|
Is ACOR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACOR income statement (TTM)|
|Cost of Revenue||US$41.77m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.88|
|Net Profit Margin||-97.41%|
How did ACOR perform over the long term?See historical performance and comparison
Is ACOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ACOR?
Other financial metrics that can be useful for relative valuation.
|What is ACOR's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ACOR's PS Ratio compare to its peers?
|ACOR PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
NAVB Navidea Biopharmaceuticals
STAB Statera Biopharma
ENSC Ensysce Biosciences
ACOR Acorda Therapeutics
Price-To-Sales vs Peers: ACOR is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (22.9x).
Price to Earnings Ratio vs Industry
How does ACOR's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: ACOR is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Biotechs industry average (14x)
Price to Sales Ratio vs Fair Ratio
What is ACOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.07x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ACOR's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ACOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ACOR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ACOR's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Acorda Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Acorda Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of ACOR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How has Acorda Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACOR is currently unprofitable.
Growing Profit Margin: ACOR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACOR is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year.
Accelerating Growth: Unable to compare ACOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: ACOR has a negative Return on Equity (-135.19%), as it is currently unprofitable.
Discover strong past performing companies
How is Acorda Therapeutics's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ACOR's short term assets ($76.5M) exceed its short term liabilities ($41.1M).
Long Term Liabilities: ACOR's short term assets ($76.5M) do not cover its long term liabilities ($277.3M).
Debt to Equity History and Analysis
Debt Level: ACOR's net debt to equity ratio (184.1%) is considered high.
Reducing Debt: ACOR's debt to equity ratio has increased from 47.7% to 210.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACOR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ACOR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.8% each year
Discover healthy companies
What is Acorda Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Acorda Therapeutics Dividend Yield vs Market|
|Company (Acorda Therapeutics)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Acorda Therapeutics)||n/a|
Notable Dividend: Unable to evaluate ACOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACOR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACOR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ACOR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ron Cohen (66 yo)
Dr. Ron Cohen, M.D., has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer and President since 1995. Dr. Cohen served as Principal in the startup of Advanced...
CEO Compensation Analysis
|Ron Cohen's Compensation vs Acorda Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$2m||US$743k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$2m||US$796k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$2m||US$796k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$2m||US$796k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$2m||US$792k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$3m||US$773k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$3m||US$769k|
Compensation vs Market: Ron's total compensation ($USD1.65M) is above average for companies of similar size in the US market ($USD772.75K).
Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.
Experienced Management: ACOR's management team is considered experienced (4.2 years average tenure).
Experienced Board: ACOR's board of directors are seasoned and experienced ( 20.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|17 Mar 22||SellUS$3,895||Ron Cohen||Individual||2,289||US$1.70|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 118.8%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Acorda Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Acorda Therapeutics, Inc.
- Ticker: ACOR
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$8.928m
- Shares outstanding: 24.33m
- Website: https://www.acorda.com
Number of Employees
- Acorda Therapeutics, Inc.
- 420 Saw Mill River Road
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CDG0||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2006|
|ACOR||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Feb 2006|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/06 00:00|
|End of Day Share Price||2022/10/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.